逸達生物科技 Foresee Pharmaceuticals Co., Ltd.
  • About Us
    • Company Profile
    • Business Model
    • Board of Directors
    • Management Team
    • Scientific Advisory Board
    • Others
  • R & D
    • Pipeline Overview
    • SIF Pipeline
      • FP-001:Prostate Cancer; Central Precocious Puberty
      • FP-004:Opioid Dependence/Pain
      • FP-011:Breast Cancer
      • FP-014:Prostate Cancer
      • FP-016:Neurology/Psychiatry
      • Other Research Projects
    • NCE Pipeline
      • FP-025:Asthma; ARDS in COVID-19 Patients; Acute Exacerbations of COPD/ILD
      • FP-045: Fanconi Anemia; Cardiovascular, Renal and Metabolism (CVRM); Peripheral artery disease (PAD)
      • FP-020: Sarcoidosis, Idiopathic pulmonary fibrosis (IPF), emphysema
      • FP-040: CNS Diseases
  • Media
    • Press Release
    • Media Library
  • Investors
    • Corporate Governance
      • Corporate Structure
      • Board of Directors
      • Corporate Charters
      • Others
    • Material Information
    • News & Events
      • Press Releases
      • Events & Presentations
    • Financial Information
      • Financial Results
      • Monthly Revenues
    • Sharholder Information
      • Annual General Meeting
      • Major Shareholders
      • FAQs
      • Investor Contacts
    • Others
  • Career
    • Welfare & Benefits
    • Join Us
  • Contact Us
  • 繁體中文
  • HOME
  • 繁體中文
  • HOME
Latest News
Foresee Pharmaceuticals Announces European Commission Approval of CAMCEVI® for the Treatment of Advanced Prostate Cancer; Accord Healthcare to Head the E.U. Commercialization
Accord BioPharma, in Partnership with Foresee Pharmaceuticals, Launches CAMCEVI™ (Leuprolide) Injection Emulsion in the U.S. for the Treatment of Advanced Prostate Cancer in Adults
Foresee Pharmaceuticals and TRPharm Announce License and Co-Development Agreement
Foresee Pharmaceuticals Announces FDA Approval of CAMCEVI® for the Treatment of Advanced Prostate Cancer; Accord BioPharma to Head the U.S. Commercialization
Foresee Pharmaceuticals Announces Dosing of First Patient in Phase 2/3 Clinical Trial of FP-025 for Treatment of COVID-19 Associated ARDS
Foresee Pharmaceuticals Enters Exclusive License Agreement with Intas Pharmaceuticals for Commercialization in the United States
Foresee Pharmaceuticals Enters Exclusive License Agreement with GenSci for the Commercialization of Camcevi in China
Foresee Pharmaceuticals Announces Completion of US$47 Million Financing
  • Press Release

  • Pipeline Overview

  • Financial Information

  • Join Us

Foresee Pharmaceuticals Co., Ltd.

Copyright © 2020 Foresee Pharmaceuticals Co., Ltd. All rights reserved.